Boardwalk Auto Luxury Texas Dealerships sold to US Auto Trust

National Bank of Bahrain (NBB) reported Q2 net profit attributable to shareholders up 16% to BD22.5 million ($59.7 million), driven mainly by higher net interest income and favourable mark-to-market movements in its bond portfolio. H1 profit fell 9% to BD43.1 million. NBB proposed an interim cash dividend of 10% (10 fils/share), subject to approval.

ORIC Pharmaceuticals presented promising Phase 1b data for enozertinib, an EGFR inhibitor, in NSCLC patients with atypical mutations. The drug showed 84% systemic ORR and 70% intracranial ORR. ORIC plans a global Phase 3 trial in 2027, enrolling 360 patients. Enozertinib was generally well-tolerated. ORIC stock is currently at $12.90, down 5.49%.

TG Therapeutics (TGTX) shared initial Phase 1 data for azer-cel in 26 progressive MS patients, showing B-cell depletion and stable or improved disability in 18 evaluable patients, with five showing EDSS improvements. Follow-up is short, and dose escalation continues.

TG Therapeutics reported initial results from a Phase 1 study of azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive MS patients. No severe side effects were observed, and 89% of evaluable patients had stable or improved disability scores. Michael S. Weiss, CEO, highlighted the potential of this off-the-shelf therapy for progressive MS. The study included 26 participants with a median follow-up of 4.9 months.

Perspective Therapeutics reported interim results for VMT-α-NET, showing 33% and 50% objective response rates in two dose cohorts and 72% progression-free survival at 18 months across all cohorts. The company plans to initiate Phase 3 trials in 2027, pending regulatory alignment.

Perspective Therapeutics (CATX) reported interim Phase 1/2a trial results for [212Pb]VMT-α-NET in neuroendocrine tumor patients. Cohort 2 showed 33% response rate (n=46) and Cohort 3 showed 50% (n=20). Disease control rates were 89% and 95% respectively. No severe adverse events were reported. The company plans to initiate Phase 3 trials in 2027.